

Josef S Smolen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4455901/publications.pdf>

Version: 2024-02-01

447
papers

73,740
citations

2091

103
h-index

691

261
g-index

454
all docs

454
docs citations

454
times ranked

38479
citing authors

#	ARTICLE	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
3	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.5	2,994
4	Rheumatoid arthritis. <i>Lancet</i> , The, 2016, 388, 2023-2038.	6.3	2,989
5	Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1594-1602.	13.9	2,910
6	Infliximab (chimeric anti-tumour necrosis factor $\hat{\pm}$ monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. <i>Lancet</i> , The, 1999, 354, 1932-1939.	6.3	2,266
7	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
8	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.5	1,711
9	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.5	1,688
10	Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor γ monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1998, 41, 1552-1563.	6.7	1,560
11	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001.	18.1	1,441
12	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.5	1,429
13	Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. <i>Lancet</i> , The, 2008, 371, 987-997.	6.3	1,269
14	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
15	Diagnosis and Management of Rheumatoid Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1360.	3.8	1,257
16	Dickkopf-1 is a master regulator of joint remodeling. <i>Nature Medicine</i> , 2007, 13, 156-163.	15.2	1,161
17	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
18	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098

#	ARTICLE	IF	CITATIONS
19	Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 3432-3443.	6.7	1,080
20	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
21	New therapies for treatment of rheumatoid arthritis. <i>Lancet, The</i> , 2007, 370, 1861-1874.	6.3	859
22	Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. <i>Arthritis Research</i> , 2005, 7, R796.	2.0	838
23	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
24	Therapeutic strategies for rheumatoid arthritis. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 473-488.	21.5	727
25	Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. <i>Lancet, The</i> , 1999, 353, 259-266.	6.3	706
26	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.5	657
27	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.5	609
28	Inflammatory bone loss: pathogenesis and therapeutic intervention. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 234-250.	21.5	601
29	Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). <i>Arthritis and Rheumatism</i> , 2005, 52, 1227-1236.	6.7	583
30	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.5	558
31	Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 2501-2512.	6.7	524
32	EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 804-814.	0.5	504
33	Baricitinib in Patients with Refractory Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2016, 374, 1243-1252.	13.9	499
34	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor $\hat{\pm}$ inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. <i>Lancet, The</i> , 2009, 374, 210-221.	6.3	497
35	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
36	2019 Update of the Joint European League Against Rheumatism and European Renal Associationâ€™European Dialysis and Transplant Association (EULAR/ERAâ€™EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 713-723.	0.5	463

#	ARTICLE	IF	CITATIONS
37	Osteoclasts are essential for TNF- α -mediated joint destruction. <i>Journal of Clinical Investigation</i> , 2002, 110, 1419-1427.	3.9	437
38	Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. <i>Arthritis and Rheumatism</i> , 2005, 52, 2625-2636.	6.7	428
39	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.5	397
40	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920.	0.5	394
41	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.5	393
42	Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 702-710.	6.7	390
43	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2015, 11, 276-289.	3.5	372
44	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet, The</i> , 2017, 390, 457-468.	6.3	360
45	Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 811-818.	0.5	325
46	Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. <i>Lancet, The</i> , 2013, 381, 918-929.	6.3	311
47	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1101-1136.	0.5	277
48	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 16-22.	0.5	275
49	Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1441-1447.	0.5	274
50	2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 16-24.	0.5	273
51	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.5	268
52	Osteoclasts are essential for TNF- α -mediated joint destruction. <i>Journal of Clinical Investigation</i> , 2002, 110, 1419-1427.	3.9	255
53	Nuclear antigen histone H1 is primarily involved in lupus erythematosus cell formation. <i>Arthritis and Rheumatism</i> , 1998, 41, 1446-1455.	6.7	244
54	Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. <i>Arthritis and Rheumatism</i> , 2006, 54, 2784-2792.	6.7	241

#	ARTICLE	IF	CITATIONS
55	Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. <i>Arthritis and Rheumatism</i> , 2011, 63, 1281-1288.	6.7	240
56	Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. <i>Arthritis and Rheumatism</i> , 2009, 60, 2747-2756.	6.7	237
57	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. <i>Lancet</i> , The, 2019, 393, 2303-2311.	6.3	237
58	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet</i> , The, 2014, 383, 321-332.	6.3	232
59	Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. <i>Arthritis and Rheumatism</i> , 1995, 38, 38-43.	6.7	226
60	Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2007, 56, 3226-3235.	6.7	225
61	Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 3-5.	0.5	212
62	SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1345-1350.	0.5	211
63	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. <i>Journal of Rheumatology</i> , 2019, 46, 7-18.	1.0	207
64	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 123-131.	0.5	206
65	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 760-770.	0.5	205
66	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.5	204
67	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 638-643.	0.5	203
68	A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 1114-1121.	0.9	198
69	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1113-1136.	0.5	195
70	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 64-71.	0.5	183
71	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213030.	0.5	183
72	Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. <i>Arthritis and Rheumatism</i> , 2010, 62, 33-43.	6.7	181

#	ARTICLE	IF	CITATIONS
73	Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1004-1009.	0.5	179
74	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 165-174.	0.5	173
75	Efficacy and Safety of ABT494, a Selective JAK1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2016, 68, 2857-2866.	2.9	172
76	Mixed connective tissue disease: To be or not to be?. <i>Arthritis and Rheumatism</i> , 1998, 41, 768-777.	6.7	167
77	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 744-759.	0.5	167
78	A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities: I. Precision, sensitivity, and specificity. <i>Arthritis and Rheumatism</i> , 1999, 42, 455-464.	6.7	163
79	Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1982, 72, 783-790.	0.6	160
80	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.5	160
81	Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 733-739.	0.5	159
82	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.5	158
83	A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 58-64.	0.5	146
84	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. <i>Lancet</i> , The, 2016, 388, 2763-2774.	6.3	144
85	Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants. <i>Arthritis and Rheumatism</i> , 2011, 63, 43-52.	6.7	141
86	The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 495-502.	0.5	136
87	Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept) Tj ETQq1 1 0.784314 rgBT /Over therapy. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1616-1625.	0.5	135
88	The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 663-675.	1.4	134
89	How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. <i>Arthritis and Rheumatism</i> , 2002, 47, 215-218.	6.7	132
90	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1102-1107.	0.5	131

#	ARTICLE	IF	CITATIONS
91	Repair of Local Bone Erosions and Reversal of Systemic Bone Loss Upon Therapy with Anti-Tumor Necrosis Factor in Combination with Osteoprotegerin or Parathyroid Hormone in Tumor Necrosis Factor-Mediated Arthritis. <i>American Journal of Pathology</i> , 2004, 164, 543-555.	1.9	130
92	Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. <i>Arthritis Care and Research</i> , 2018, 70, 428-438.	1.5	129
93	The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 9-44.	0.8	124
94	A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 831-839.	0.5	124
95	Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. <i>Arthritis and Rheumatism</i> , 2011, 63, 3702-3711.	6.7	122
96	Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 687-693.	0.5	119
97	Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 114-123.	0.5	118
98	Impact of comorbidity on physical function in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 536-541.	0.5	117
99	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.5	114
100	Demonstration of a new antinuclear antibody (ANTI-RA33) that is highly specific for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1989, 32, 1515-1520.	6.7	113
101	Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1757-1764.	0.5	113
102	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 534-542.	0.5	111
103	Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 381-388.	0.9	109
104	Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. <i>Journal of Rheumatology</i> , 2013, 40, 768-780.	1.0	108
105	Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. <i>Arthritis Research and Therapy</i> , 2014, 16, R56.	1.6	108
106	Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 234-240.	0.5	107
107	Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 778-786.	0.5	104
108	Multimorbidity and rheumatic conditions "enhancing the concept of comorbidity. <i>Nature Reviews Rheumatology</i> , 2014, 10, 252-256.	3.5	103

#	ARTICLE	IF	CITATIONS
109	Therapeutic blockade of TNF in patients with SLE – Promising or crazy?. <i>Autoimmunity Reviews</i> , 2012, 11, 321-325.	2.5	102
110	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102
111	Interleukin-6: a new therapeutic target. <i>Arthritis Research and Therapy</i> , 2006, 8, S5.	1.6	101
112	Alterations of dendritic cells in systemic lupus erythematosus: Phenotypic and functional deficiencies. <i>Arthritis and Rheumatism</i> , 2001, 44, 856-865.	6.7	98
113	Forget personalised medicine and focus on abating disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 3-6.	0.5	98
114	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 490-498.	0.5	98
115	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	1.1	97
116	Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1058-1064.	0.5	95
117	Clocking in: chronobiology in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2015, 11, 349-356.	3.5	91
118	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. <i>Arthritis Care and Research</i> , 2018, 70, 571-581.	1.5	91
119	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.5	89
120	Validating the International Classification of Functioning, Disability and Health Comprehensive Core Set for Rheumatoid Arthritis from the patient perspective: A qualitative study. <i>Arthritis and Rheumatism</i> , 2005, 53, 431-439.	6.7	88
121	The pathogenesis of rheumatoid arthritis: new insights from old clinical data?. <i>Nature Reviews Rheumatology</i> , 2012, 8, 235-243.	3.5	86
122	Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 79-88.	6.7	84
123	Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. <i>Journal of Rheumatology</i> , 2002, 29, 1631-8.	1.0	83
124	Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. <i>Arthritis and Rheumatism</i> , 2007, 57, 487-494.	6.7	82
125	Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1190-1196.	0.5	82
126	Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 902-905.	0.5	82

#	ARTICLE	IF	CITATIONS
127	Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 583-589.	0.5	80
128	Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?. <i>Arthritis and Rheumatism</i> , 2005, 52, 2975-2983.	6.7	77
129	Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. <i>Journal of Experimental Medicine</i> , 2016, 213, 1937-1950.	4.2	75
130	Therapeutic strategies in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 163-177.	1.4	74
131	The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2015, 54, 2076-2084.	0.9	74
132	Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: A systematic review. <i>Arthritis Care and Research</i> , 2010, 62, 108-117.	1.5	73
133	Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 229.	1.6	73
134	Activation of Fas inhibits heat-induced activation of HSF1 and up-regulation of hsp70. <i>FASEB Journal</i> , 1999, 13, 833-842.	0.2	72
135	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	2.9	72
136	Severe infections in plasmapheresis-treated systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998, 41, 414-420.	6.7	71
137	The patient perspective on remission in rheumatoid arthritis: "You've got limits, but you're back to being you again". <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1004-1010.	0.5	71
138	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016, 12, 743-750.	3.5	71
139	Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 335-343.	0.5	71
140	Characterization of Autoreactive T Cells to the Autoantigens Heterogeneous Nuclear Ribonucleoprotein A2 (RA33) and Filaggrin in Patients with Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2002, 169, 1068-1076.	0.4	70
141	The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?. <i>Arthritis Research and Therapy</i> , 2008, 10, 208.	1.6	69
142	Cytokines as Therapeutic Targets: Advances and Limitations. <i>Immunity</i> , 2008, 28, 440-444.	6.6	69
143	Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 875-880.	0.5	69
144	Regulatory T cell-deficient scurfy mice develop systemic autoimmune features resembling lupus-like disease. <i>Arthritis Research and Therapy</i> , 2015, 17, 35.	1.6	68

#	ARTICLE	IF	CITATIONS
145	Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1145-1149.	0.5	68
146	Pro-Inflammatory Cytokines in Rheumatoid Arthritis: Pathogenetic and Therapeutic Aspects. <i>Clinical Reviews in Allergy and Immunology</i> , 2005, 28, 239-248.	2.9	67
147	Era of biosimilars in rheumatology: reshaping the healthcare environment. <i>RMD Open</i> , 2019, 5, e000900.	1.8	67
148	Measuring functioning in patients with hand osteoarthritis--content comparison of questionnaires based on the International Classification of Functioning, Disability and Health (ICF). <i>Rheumatology</i> , 2006, 45, 1534-1541.	0.9	66
149	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 171-178.	0.5	66
150	Non-classical monocytes as mediators of tissue destruction in arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1490-1497.	0.5	65
151	I Have Mastered the Challenge of Living With a Chronic Disease: Life Stories of People With Rheumatoid Arthritis. <i>Qualitative Health Research</i> , 2008, 18, 658-669.	1.0	64
152	Reporting of long-term extension studies: lack of consistency calls for consensus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 886-890.	0.5	64
153	Criteria for early rheumatoid arthritis: From Bayes' law revisited to new thoughts on pathogenesis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1155-1159.	6.7	63
154	Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1631-1640.	0.5	63
155	Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1479-1485.	0.5	63
156	mTOR Senses Environmental Cues to Shape the Fibroblast-like Synoviocyte Response to Inflammation. <i>Cell Reports</i> , 2018, 23, 2157-2167.	2.9	62
157	Risk profiling for a refractory course of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 211-217.	1.6	62
158	Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. <i>Arthritis and Rheumatism</i> , 2007, 57, 1287-1295.	6.7	61
159	The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 855-861.	0.5	61
160	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1290-1297.	0.5	61
161	Infliximab: 12 years of experience. <i>Arthritis Research and Therapy</i> , 2011, 13, S2.	1.6	60
162	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208.	0.5	59

#	ARTICLE	IF	CITATIONS
163	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 167-173.	1.6	58
164	Safety and efficacy of biosimilars in oncology. <i>Lancet Oncology</i> , The, 2016, 17, e502-e509.	5.1	58
165	Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. <i>Arthritis and Rheumatism</i> , 1997, 40, 413-418.	6.7	56
166	The concurrence of rheumatoid arthritis and limited systemic sclerosis: Clinical and serologic characteristics of an overlap syndrome. <i>Arthritis and Rheumatism</i> , 1998, 41, 1938-1945.	6.7	56
167	Developments in the clinical understanding of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009, 11, 204.	1.6	56
168	Sonographic Joint Assessment in Rheumatoid Arthritis: Associations With Clinical Joint Assessment During a State of Remission. <i>Arthritis and Rheumatism</i> , 2013, 65, 2005-2014.	6.7	56
169	Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1156-1162.	0.5	56
170	Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1310-1319.	0.5	56
171	Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1975-1980.	0.5	54
172	A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1598-1602.	0.5	54
173	Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1671-1679.	0.5	53
174	Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. <i>Rheumatology</i> , 2015, 54, 994-1007.	0.9	51
175	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 634-640.	0.5	51
176	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. <i>Arthritis Research and Therapy</i> , 2015, 17, 14.	1.6	49
177	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. <i>Rheumatology</i> , 2017, 56, 1771-1779.	0.9	49
178	Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018, 9, 876.	2.2	49
179	IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-11.	3.2	49
180	Tocilizumab. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 273-274.	21.5	48

#	ARTICLE	IF	CITATIONS
181	Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001095.	1.8	48
182	Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 575-578.	0.5	47
183	Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 710-720.	0.9	47
184	Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 900-908.	0.9	47
185	The need for new classification criteria for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3333-3336.	6.7	46
186	Development of a new occupational balance-questionnaire: incorporating the perspectives of patients and healthy people in the design of a self-reported occupational balance outcome instrument. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 45.	1.0	45
187	Treat-to-target as an approach in inflammatory arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 297-302.	2.0	45
188	Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. <i>Nature Reviews Rheumatology</i> , 2019, 15, 633-634.	3.5	45
189	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	1.0	45
190	Tumor necrosis factor- α inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor- α driven model of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 608-617.	6.7	44
191	Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 241-244.	0.5	44
192	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. <i>Modern Rheumatology</i> , 2020, 30, 36-43.	0.9	44
193	Mechanisms of tissue damage in arthritis. <i>Seminars in Immunopathology</i> , 2014, 36, 531-540.	2.8	43
194	MicroRNA-146a governs fibroblast activation and joint pathology in arthritis. <i>Journal of Autoimmunity</i> , 2017, 82, 74-84.	3.0	43
195	Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. <i>Advances in Therapy</i> , 2017, 34, 91-108.	1.3	43
196	Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 687-694.	0.5	43
197	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 445-452.	0.5	42
198	Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 1519-1534.	1.1	42

#	ARTICLE	IF	CITATIONS
199	Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 227-233.	0.5	41
200	Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 838-844.	0.5	41
201	Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 1374-1380.	2.9	40
202	Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study. <i>Journal of Rheumatology</i> , 2015, 42, 1099-1104.	1.0	39
203	Biosimilar safety factors in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, S9-S15.	1.6	39
204	Preservation of cartilage and bone architecture is the most important aspect for maintaining functionality in longstanding experimental arthritis. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 1329-1338.	1.2	39
205	Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. <i>Arthritis and Rheumatology</i> , 2017, 69, 728-734.	2.9	39
206	Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000546.	1.8	39
207	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	1.5	39
208	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). <i>RMD Open</i> , 2016, 2, e000221.	1.8	38
209	The effects of structural damage on functional disability in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2038-2045.	0.5	38
210	Health determining concepts important to people with Crohn's disease and their coverage by patient-reported outcomes of health and wellbeing. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 45-55.	0.6	37
211	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). <i>Arthritis Research and Therapy</i> , 2015, 17, 157.	1.6	37
212	Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. <i>Vaccine</i> , 2018, 36, 4875-4879.	1.7	37
213	Environmental arginine controls multinuclear giant cell metabolism and formation. <i>Nature Communications</i> , 2020, 11, 431.	5.8	37
214	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
215	Systemic Lupus Erythematosus: Delineation of Subpopulations by Clinical, Serologic, and T Cell Subset Analysis. <i>American Journal of the Medical Sciences</i> , 1985, 289, 139-147.	0.4	36
216	Developing an effective treatment algorithm for rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, v48-v54.	0.9	36

#	ARTICLE	IF	CITATIONS
217	Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1335-1341.	0.5	36
218	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.5	36
219	New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. <i>Rheumatology</i> , 2017, 56, kew390.	0.9	36
220	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374.	1.8	36
221	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.5	36
222	Patient global assessment in psoriatic arthritis – what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. <i>Joint Bone Spine</i> , 2016, 83, 335-340.	0.8	35
223	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , 2020, 7, e000424.	1.1	35
224	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
225	Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1465-74.	1.0	34
226	Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1609-1615.	0.5	33
227	I Would Never Take Preventive Medication! Perspectives and Information Needs of People Who Underwent Predictive Tests for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 360-368.	1.5	33
228	Activity assessments in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 306-313.	2.0	32
229	Monitoring rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 252-258.	2.0	32
230	Perceptions of risk and predictive testing held by the first-degree relatives of patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study. <i>BMJ Open</i> , 2016, 6, e010555.	0.8	32
231	Nicotinic acetylcholine receptors modulate osteoclastogenesis. <i>Arthritis Research and Therapy</i> , 2016, 18, 63.	1.6	32
232	Targeted inhibition of Janus kinases abates interferon gamma-induced invasive behaviour of fibroblast-like synoviocytes. <i>Rheumatology</i> , 2018, 57, 572-577.	0.9	32
233	Interferon signals and monocytic sensitization of the interferon- γ signaling pathway in the peripheral blood of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 400-408.	6.7	31
234	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1567-1570.	0.5	31

#	ARTICLE	IF	CITATIONS
235	Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis management. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 18-20.	0.5	31
236	Treat to Target in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 477-485.	0.8	31
237	Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis. <i>Journal of Autoimmunity</i> , 2020, 108, 102379.	3.0	31
238	MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus. <i>PLoS ONE</i> , 2017, 12, e0181015.	1.1	30
239	Response to: "Comment on: EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update" by Gossec et al. by Wei et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e139-e139.	0.5	30
240	Greetings from the editor. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 677-678.	0.5	30
241	Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for Psoriatic Arthritis (DAPSA). A brief review. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S48-50.	0.4	30
242	Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1811-1818.	0.5	29
243	Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. <i>RMD Open</i> , 2018, 4, e000564.	1.8	29
244	Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 8.	1.6	29
245	Clinical and immunological aspects of autoantibodies to RA33/hnRNP-A/B proteins ? A link between RA, SLE and MCTD. <i>Molecular Biology Reports</i> , 1996, 23, 167-171.	1.0	28
246	Rheumatoid arthritis is more than cytokines: Autoimmunity and rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2218-2220.	6.7	28
247	When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1497-1498.	0.5	28
248	Definitions of occupational balance and their coverage by instruments. <i>British Journal of Occupational Therapy</i> , 2015, 78, 4-15.	0.5	28
249	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. <i>RMD Open</i> , 2019, 5, e001040.	1.8	28
250	Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 884-890.	0.5	28
251	Insights into the treatment of rheumatoid arthritis: A paradigm in medicine. <i>Journal of Autoimmunity</i> , 2020, 110, 102425.	3.0	27
252	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1268-1271.	0.5	26

#	ARTICLE	IF	CITATIONS
253	Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial. <i>Rheumatology</i> , 2018, 57, 1933-1937.	0.9	26
254	Contributions of ultrasound beyond clinical data in assessing inflammatory disease activity in rheumatoid arthritis: current insights and future prospects. <i>Rheumatology</i> , 2014, 53, 2136-2142.	0.9	25
255	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 276-284.	1.6	25
256	Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 7-12.	0.5	24
257	Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17-mediated autoimmune arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 230.	1.6	24
258	Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , 2017, 69, 720-727.	2.9	24
259	MicroRNA-155 Controls T Helper Cell Activation During Viral Infection. <i>Frontiers in Immunology</i> , 2019, 10, 1367.	2.2	24
260	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 164.	1.6	24
261	The assessment of disease activity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S18-27.	0.4	24
262	Information technology in rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1.	0.4	24
263	Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 203.	1.6	23
264	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015, 54, 1630-1639.	0.9	23
265	Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1566-1572.	0.5	23
266	Challenges of predicting treatment response in patients with rheumatoid arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 62-63.	3.2	22
267	Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure. <i>Arthritis Research and Therapy</i> , 2006, 8, R46.	1.6	22
268	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 289-292.	0.5	22
269	Functional consultation and exercises improve grip strength in osteoarthritis of the hand – a randomised controlled trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 253.	1.6	22
270	Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 709-718.	1.6	22

#	ARTICLE	IF	CITATIONS
271	Treat-to-target: rationale and strategies. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S2-6.	0.4	22
272	Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 153-164.	0.9	21
273	Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. <i>Rheumatology and Therapy</i> , 2020, 7, 1021-1035.	1.1	21
274	Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1403-1406.	0.5	20
275	A Combination of CD28 (rs1980422) and IRF5 (rs10488631) Polymorphisms Is Associated with Seropositivity in Rheumatoid Arthritis: A Case Control Study. <i>PLoS ONE</i> , 2016, 11, e0153316.	1.1	20
276	Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. <i>Journal of Rheumatology</i> , 2016, 43, 203-207.	1.0	20
277	FOXO3 is involved in the tumor necrosis factor-driven inflammatory response in fibroblast-like synoviocytes. <i>Laboratory Investigation</i> , 2019, 99, 648-658.	1.7	20
278	Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 245-251.	1.6	20
279	microRNA-146a controls age-related bone loss. <i>Aging Cell</i> , 2020, 19, e13244.	3.0	20
280	Rheumatoid arthritis Primer " behind the scenes. <i>Nature Reviews Disease Primers</i> , 2020, 6, 32.	18.1	20
281	Treatment of psoriatic arthritis: management recommendations. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S73-7.	0.4	20
282	CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 6.	1.6	19
283	Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 81-87.	1.6	18
284	Relation of Nailfold Capillaries and Autoantibodies to Mortality in Patients With Raynaud Phenomenon. <i>Circulation</i> , 2016, 133, 509-517.	1.6	18
285	How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 782-783.	0.5	18
286	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 174.	1.6	18
287	Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. <i>Rheumatology and Therapy</i> , 2019, 6, 409-419.	1.1	18
288	Greetings from the editor 2019. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1-2.	0.5	18

#	ARTICLE	IF	CITATIONS
289	Greetings from the editor 2020. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1-2.	0.5	18
290	The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. <i>Journal of rheumatology Supplement, The</i> , 2004, 71, 13-20.	2.2	18
291	Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 823-830.	0.5	18
292	Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 133.	1.6	17
293	Do patient-reported outcome measures cover personal factors important to people with rheumatoid arthritis? A mixed methods design using the International Classification of Functioning, Disability and Health as frame of reference. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 27.	1.0	17
294	Disease activity assessment in patients with psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 401-414.	1.4	17
295	Achieving Clinical Remission for Patients With Rheumatoid Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 457.	3.8	17
296	Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1419-1428.	0.5	17
297	Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 874-882.	0.5	16
298	Therapy of systemic lupus erythematosus: a look into the future. <i>Arthritis Research</i> , 2002, 4, S25.	2.0	15
299	Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. <i>Rheumatology</i> , 2016, 55, 1458-1465.	0.9	15
300	Clinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 193-198.	1.6	14
301	Response to: "Correspondence on EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update" by Fallon et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e174-e174.	0.5	14
302	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. <i>Joint Bone Spine</i> , 2020, 87, 449-454.	0.8	14
303	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , 2021, 60, 256-262.	0.9	14
304	Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 937-943.	0.5	14
305	The American College of Rheumatology N (ACR-N) debate: Going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers. <i>Arthritis and Rheumatism</i> , 2006, 54, 377-378.	6.7	13
306	Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. <i>RMD Open</i> , 2018, 4, e000602.	1.8	13

#	ARTICLE	IF	CITATIONS
307	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020, 59, 1842-1852.	0.9	13
308	Greetings from the editor 2021. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1-3.	0.5	13
309	Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e67-e67.	0.5	12
310	Initial evidence for the link between activities and health: Associations between a balance of activities, functioning and serum levels of cytokines and C-reactive protein. <i>Psychoneuroendocrinology</i> , 2016, 65, 138-148.	1.3	12
311	Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns. <i>PLoS ONE</i> , 2019, 14, e0219698.	1.1	12
312	An intergenerational program based on psycho-motor activity promotes well-being and interaction between preschool children and older adults: results of a process and outcome evaluation study in Austria. <i>BMC Public Health</i> , 2019, 19, 254.	1.2	12
313	Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 593-602.	1.5	12
314	Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. <i>Rheumatology</i> , 2021, 60, 2256-2266.	0.9	12
315	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021, 7, e001637.	1.8	12
316	Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 2815-2825.	0.9	12
317	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760.	0.5	11
318	Benefits and Sustainability of a Learning Collaborative for Implementation of Treatment Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase Clinical Trial. <i>Arthritis Care and Research</i> , 2018, 70, 1551-1556.	1.5	11
319	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. <i>Journal of Rheumatology</i> , 2019, 46, 1159-1163.	1.0	11
320	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431.	0.5	11
321	Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 115.	1.6	11
322	Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 532-537.	0.5	10
323	CCR6 controls autoimmune but not innate immunity-driven experimental arthritis. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5278-5285.	1.6	10
324	Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. <i>RMD Open</i> , 2018, 4, e000773.	1.8	9

#	ARTICLE	IF	CITATIONS
325	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. <i>Rheumatology and Therapy</i> , 2018, 5, 341-353.	1.1	9
326	Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology. <i>Nature Medicine</i> , 2020, 26, 974-980.	15.2	9
327	Response to: "Correspondence on "Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement" by Banday et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e105-e105.	0.5	9
328	How well can we compare different biologic agents for RA?. <i>Nature Reviews Rheumatology</i> , 2010, 6, 247-248.	3.5	8
329	Multimodal [18F]FDG PET/CT Is a Direct Readout for Inflammatory Bone Repair: A Longitudinal Study in TNF± Transgenic Mice. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1632-1645.	3.1	8
330	Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110225.	1.2	8
331	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1108-1112.	1.6	8
332	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 601-606.	1.6	7
333	Information technology concerning SDAI and CDAI. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S45-S48.	0.4	7
334	Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials. <i>Journal of Rheumatology</i> , 2016, 43, 1024-1026.	1.0	6
335	Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2019, 21, 231.	1.6	6
336	FRIO193...2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
337	Treatment "Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. <i>Arthritis Care and Research</i> , 2020, 72, 814-821.	1.5	6
338	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 643-644.	1.6	6
339	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 242-249.	0.5	6
340	Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 175-183.	0.5	6
341	Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1374-1378.	0.5	6
342	Reply:. <i>Arthritis and Rheumatism</i> , 2005, 52, 4045-4047.	6.7	5

#	ARTICLE	IF	CITATIONS
343	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. <i>RMD Open</i> , 2017, 3, e000445.	1.8	5
344	THU0078â€¦SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. , 2019, , .		5
345	Greetings from the editor 2022. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1-3.	0.5	5
346	Ten years of infliximab: Insights from clinical trials in rheumatoid arthritis. <i>European Journal of Pharmacology</i> , 2009, 623, S5-S9.	1.7	4
347	Interphalangeal Osteoarthritis Radiographic Simplified (iOARS) score: a radiographic method to detect osteoarthritis of the interphalangeal finger joints based on its histopathological alterations. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1983-1989.	0.5	4
348	Response to: â€˜2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?â€™ by Misra et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e48-e48.	0.5	4
349	The new editor greets you. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1636-1636.	0.5	4
350	Contribution of Genetic Factors to Lower DHEAS in Patients with Rheumatoid Arthritis. <i>Cellular and Molecular Neurobiology</i> , 2018, 38, 379-383.	1.7	4
351	Considering new lessons about the use of IL-6 inhibitors in arthritis. <i>Considerations in Medicine</i> , 2018, 2, 7-11.	0.0	4
352	Effects of a brief workplace-centered consultation for employees with musculoskeletal pain on health outcomes: a prospective cohort study. <i>Scientific Reports</i> , 2019, 9, 5867.	1.6	4
353	185â€¦Baricitinib-associated changes in type I interferon gene signature during a 24-week phase 2 clinical SLE trial. , 2019, , .		4
354	Whatâ€¦influences patientsâ€™ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. <i>Rheumatology</i> , 2021, 60, 5292-5299.	0.9	4
355	What is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trials. <i>Journal of Rheumatology Supplement</i> , The, 2007, 79, 15-20.	2.2	4
356	Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 622-631.	0.5	4
357	Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, 49, 694-699.	1.0	4
358	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. <i>RMD Open</i> , 2022, 8, e002031.	1.8	4
359	Expanding the frontiers of therapy. <i>Arthritis Research and Therapy</i> , 2006, 8, S1.	1.6	3
360	Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 296-297.	3.2	3

#	ARTICLE	IF	CITATIONS
361	Opportunities and challenges in rheumatology research in Central Europe. <i>Arthritis Research and Therapy</i> , 2017, 19, 196.	1.6	3
362	Targeting IL-6: A review of data. <i>Considerations in Medicine</i> , 2018, 2, 12-18.	0.0	3
363	e48â€fEffects of baricitinib on haematological laboratory parameters in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	3
364	To DAPSA or not to DAPSA? That is not the question. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e61-e61.	0.5	3
365	OP0007â€f...HIGH BODY MASS INDEX (BMI) IN PSORIATIC ARTHRITIS (PSA) IS ASSOCIATED WITH HIGHER DISEASE ACTIVITY IN JOINTS AND SKIN, IMPAIRED QUALITY OF LIFE AND MORE DISABILITY: RESULTS FROM THE PSABIO STUDY. , 2019, , .		3
366	THU0193â€f...EFFICACY OF TOFACITINIB MONOTHERAPY, TOFACITINIB WITH METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE IN PATIENTS WITH EARLY (&%2 YEARS) VS ESTABLISHED (>2 YEARS) RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STRATEGY. , 2019, , .		3
367	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001096.	1.8	3
368	Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2021, 384, 83-84.	13.9	3
369	Alterations of dendritic cells in systemic lupus erythematosus: Phenotypic and functional deficiencies. <i>Arthritis and Rheumatism</i> , 2001, 44, 856-865.	6.7	3
370	Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 362-370.	0.4	3
371	Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e002038.	1.8	3
372	Analysis of combined deficiency of interleukin-1 and -6 versus single deficiencies in TNF-mediated arthritis and systemic bone loss. <i>Bone and Joint Research</i> , 2022, 11, 484-493.	1.3	3
373	Response to: â€fEvidence for treating rheumatoid arthritis to target: results of a systematic literature search updateâ€™ by Goswami<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e36-e36.	0.5	2
374	245â€fRemission/low disease activity is an achievable treatment target in psoriatic arthritis (PsA): results from a routine care European cohort of PsA patients treated with ustekinumab or TNF inhibitors. <i>Rheumatology</i> , 2019, 58, .	0.9	2
375	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 188.	1.6	2
376	Greetings from the editor. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 677-678.	0.5	2
377	Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. <i>Arthritis Research and Therapy</i> , 2021, 23, 220.	1.6	2
378	Severe infections in plasmapheresis-treated systemic lupus erythematosus. , 1998, 41, 414.		2

#	ARTICLE	IF	CITATIONS
379	Response to: Where are the women â€˜Heroes and Pillars of Rheumatologyâ€™?. Annals of the Rheumatic Diseases, 2023, 82, e200-e200.	0.5	2
380	Reflections on a contemporary European tragedy. Annals of the Rheumatic Diseases, 2022, 81, 747-748.	0.5	2
381	Greetings from the editor. Annals of the Rheumatic Diseases, 2022, 81, 748-750.	0.5	2
382	On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: Comment on the article by Graudal et al. Arthritis and Rheumatism, 2011, 63, 3182-3185.	6.7	1
383	Nicotinic acetylcholine receptor activation completely blocks osteoclastogenesis by interfering with osteoclast precursor differentiation in vitro. Annals of the Rheumatic Diseases, 2011, 70, A74-A75.	0.5	1
384	A1.82â€¦Limited role of microrna 155 innate immunity dependent arthritis. Annals of the Rheumatic Diseases, 2014, 73, A36.1-A36.	0.5	1
385	Response to â€˜Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritisâ€™. Arthritis Research and Therapy, 2015, 17, 166.	1.6	1
386	078â€¦Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors: Summary Results from the 24-Week Phase III RA-Beacon Study. Rheumatology, 0, , .	0.9	1
387	02.06â€¦Ccr6 modulates severity of arthritis in T cell dependent manner. , 2017, , .		1
388	Response to: â€˜The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studiesâ€™ by Tillet <i>et al</i>. Annals of the Rheumatic Diseases, 2018, 77, e24-e24.	0.5	1
389	219â€¦Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities. Rheumatology, 2018, 57, .	0.9	1
390	Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. Rheumatic Disease Clinics of North America, 2019, 45, 315-324.	0.8	1
391	074â€¦Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis. Rheumatology, 2019, 58, .	0.9	1
392	FRI0164â€¦INCIDENCE RATE AND CHARACTERIZATION OF HERPES ZOSTER IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: AN UPDATE FROM BARICITINIB CLINICAL STUDIES. , 2019, , .		1
393	Hand X-ray examination in two planes is not required for radiographic assessment of hand osteoarthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093493.	1.2	1
394	Response to: â€˜Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritisâ€™ by Bugatti<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e56-e56.	0.5	1
395	Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093348.	1.2	1
396	Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al. Arthritis and Rheumatology, 2020, 72, 1227-1229.	2.9	1

#	ARTICLE	IF	CITATIONS
397	Response to: "Correspondence on "Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study" by Charles. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e110-e110.	0.5	1
398	009 Safety profile of baricitinib for the treatment of RA up to 8.4 years: an updated integrated safety analysis. <i>Rheumatology</i> , 2021, 60, .	0.9	1
399	A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities: I. Precision, sensitivity, and specificity. , 1999, 42, 455.		1
400	Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. , 2017, 34, 91.		1
401	Implementing a "Treat-to-Target" Approach for Rheumatoid Arthritis During the COVID-19 Pandemic: Results of a Virtual Learning Collaborative Program. <i>Arthritis Care and Research</i> , 2022, 74, 572-578.	1.5	1
402	Objectives and strategies for rheumatoid arthritis therapy: yesterday vs. today. <i>Drugs of Today</i> , 2003, 39 Suppl B, 3-8.	0.7	1
403	The eumusc.net standards of care for rheumatoid arthritis: importance and current implementation according to patients and healthcare providers in the Netherlands. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 275-283.	0.4	1
404	P196 Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis. <i>Rheumatology</i> , 2022, 61, .	0.9	1
405	The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care. <i>Current Rheumatology Reports</i> , 2003, 5, 336-340.	2.1	0
406	Sensitisation of the IFN-Stat1-signalling-pathway in rheumatoid arthritis monocytes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A15-A16.	0.5	0
407	Combined depletion of interleukin 1 and interleukin 6 does not exceed single depletion of interleukin 1 in TNF mediated arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A72-A72.	0.5	0
408	Multi-targeted kinase inhibitor PKC412 diminishes osteoclastogenesis and counteracts osteoclast function in vitro. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A81-A81.	0.5	0
409	Micro-RNA 155 controls the pathogenesis of autoimmune arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A79-A80.	0.5	0
410	Real time in vivo analysis of granulomonocytic cell migration in the collagen induced arthritis model. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A73.2-A73.	0.5	0
411	Muscle wasting in hTNFtg mice, an animal model for rheumatoid arthritis, due to increased cathepsin L expression. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A45.1-A45.	0.5	0
412	Sustained PI3-kinase activity in myeloid cells enhances osteoclastogenesis and augments local bone destruction. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A67.1-A67.	0.5	0
413	A8.7 Functional Impairment in an Animal Model for Rheumatoid Arthritis Assessed as Changes in Gait is Due to Joint Destruction But Not Synovial Inflammation Per Se. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A59.2-A60.	0.5	0
414	A2.19 The Role of microRNA 155 in Innate Immunity and Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A11.2-A11.	0.5	0

#	ARTICLE	IF	CITATIONS
415	A9.7â€¦Loss of PTEN in Myeloid Cells Controls Inflammatory Bone Destruction by Regulating the Osteoclastogenic Potential of Myeloid Cells. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A66.3-A67.	0.5	0
416	A4.6â€¦Effects of Cholic Acid and its Derivatives in Experimental Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A25.2-A26.	0.5	0
417	A1.81â€¦Mincle is not essential in T-cell independent arthritis models. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A35.3-A36.	0.5	0
418	A8.30â€¦Analysis of monocyte-fibroblast interaction in 3D synovial micromass tissue cultures. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A88.1-A88.	0.5	0
419	Advances in targeted therapy. <i>Rheumatology</i> , 2016, 55, ii1-ii2.	0.9	0
420	Title is missing!. <i>Japanese Journal of Clinical Immunology</i> , 2016, 39, 388a-388a.	0.0	0
421	Response to: â€œThe time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritisâ€™ by PiriÅ <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e50-e50.	0.5	0
422	04.05â€¦The metabolic checkpoint kinase mtor regulates the rheumatoid mesenchymal tissue response to inflammation. , 2017, , .		0
423	08.28â€¦The prognostic value of iga autoantibodies (rheumatoid factor and acpa) for prediction of the therapeutic response to anti-tnf therapy in patients with rheumatoid arthritis. , 2017, , .		0
424	01.11â€¦Resident non-classical monocytes are critically important for tissue destruction in arthritis. , 2017, , .		0
425	04.13â€¦The transcription factor foxo3 differentially regulates the expression of proinflammatory genes in rheumatoid fibroblast-like synoviocytes. , 2017, , .		0
426	04.15â€¦Resolution of systemic inflammatory processes and regeneration of inflammation-driven bone damage upon tnf blockade as monitored by in vivo multimodal pet-ct imaging in tnf driven experimental arthritis. , 2017, , .		0
427	04.07â€¦Microrna-146a controls local bone destruction by regulating fibroblast induced osteoclastogenesis in inflammatory arthritis. , 2017, , .		0
428	226â€¦Summary of baricitinib effect on patient-reported outcomes (PROs) in methotrexate-inadequate responder patient population. <i>Rheumatology</i> , 2018, 57, .	0.9	0
429	233â€¦Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib. <i>Rheumatology</i> , 2018, 57, .	0.9	0
430	182â€¦Secukinumab provides sustained improvement in function, quality of life and fatigue over two years in patients who achieved disease activity index for psoriatic arthritis remission. <i>Rheumatology</i> , 2018, 57, .	0.9	0
431	184â€¦Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis: two year results from the FUTURE 2 study. <i>Rheumatology</i> , 2018, 57, .	0.9	0
432	Greetings from the editor. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 715-715.	0.5	0

#	ARTICLE	IF	CITATIONS
433	THU0431â€¦FREQUENCY OF TENDON INVOLVEMENT AND ITS EFFECT ON HAND FUNCTION IN HAND OSTEOARTHRITIS. , 2019, , .		0
434	AB1219â€¦EFFECTS OF A WORKPLACE-CENTERED COUNSELING OF INDIVIDUALS WITH MUSCULOSKELETAL COMPLAINTS: A PROSPECTIVE COHORT STUDY. , 2019, , .		0
435	THU0101â€¦TORQUE TENO VIRAL LOAD FOR MONITORING OF BIOLOGICAL THERAPIES IN RHEUMATOID ARTHRITIS. , 2019, , .		0
436	OPO229PHASEâ€¦II CLINICAL TRIALS SYSTEMATICALLY OVERESTIMATE TREATMENT EFFECTS OF SUBSEQUENT PHASE III TRIALS IN RHEUMATOID ARTHRITIS. , 2019, , .		0
437	SAT0061â€¦IMPORTANT ROLE OF CD11C+ CELLS IN INFLAMMATORY ARTHRITIS. , 2019, , .		0
438	SAT0162â€¦A POOLED ANALYSIS OF 1-YEAR CLINICAL OUTCOMES AMONG 6-MONTH RESPONDERS AND NON-RESPONDERS FROM THREE RANDOMISED CONTROLLED STUDIES OF TNF INHIBITOR BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
439	LB0005â€¦MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: 24-WEEK RESULTS. , 2019, , .		0
440	THU0133â€¦TENDERNESS CAN BE REGARDED AS A SIGN OF INFLAMMATION IN RHEUMATOID ARTHRITIS. , 2019, , .		0
441	P276â€¦Comparative effects of ixekizumab (IXE) vs adalimumab (ADA) across PsA patients defined by baseline characteristics: week 24 outcomes from SPIRIT-H2H. <i>Rheumatology</i> , 2020, 59, .	0.9	0
442	Response to: â€”Comment on â€”Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumabâ€”â™™ by Pethoe-Schramm <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e137-e137.	0.5	0
443	O4â€¦Baricitinib-induced changes in STAT-associated gene expression in systemic lupus erythematosus. , 2020, , .		0
444	O8â€¦Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
445	Risk of harm in synthetic and biological intervention trials in patients with inflammatory arthritis: protocol for a metaepidemiological study focusing on contextual factors. <i>BMJ Open</i> , 2021, 11, e049850.	0.8	0
446	Novel therapies in rheumatoid arthritis: small molecules. , 2015, , 251-266.		0
447	O24â€¦Concomitant treatment with MTX does not increase the efficacy of ustekinumab or TFNi in PsA: results from the PsABio study. <i>Rheumatology</i> , 2020, 59, .	0.9	0